Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

July 8th 2024

Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.

Investigating Risk-Based Treatment Strategies for Pediatric Non-Rhabdomyosarcoma Soft-Tissue Sarcoma

July 7th 2024

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

July 3rd 2024

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy

Belantamab Mafodotin–Based Combo Boosts PFS in Difficult-to-Treat R/R Myeloma Subgroups

July 1st 2024

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

Do Tumor-Naive MRD Assays Have a Role in Resected CRC? Cremolini Weighs in

June 28th 2024

Chiara Cremolini, MD, discusses the role of ctDNA in assessing minimal residual disease in patients with CRC.

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

June 26th 2024

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Sacituzumab Govitecan/Enfortumab Vedotin ± Pembrolizumab Under Investigation in Metastatic Urothelial Carcinoma

June 26th 2024

Bradley McGregor, MD, on the ongoing evaluation of sacituzumab govitecan plus enfortumab vedotin with or without pembrolizumab in urothelial carcinoma.

ARASENS Trial Demonstrates Significant Survival Benefits With Triplet Therapy in mHSPC

June 25th 2024

Darolutamide plus ADT and docetaxel showed improved outcomes in patients with metastatic hormone-sensitive prostate cancer.

Fixed-Duration Glofitamab Yields Responses in R/R Mantle Cell Lymphoma

June 18th 2024

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

DESTINY-Breast06 Data Reveal Another Potential Avenue for T-DXd in HR+, HER2-Low Metastatic Breast Cancer

June 13th 2024

VK Gadi, MD, PhD, discusses findings from the DESTINY-Breast06 trial and the implications for hormone receptor–positive, HER2-low metastatic breast cancer.

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

June 11th 2024

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.

Factors for JAK Inhibitor Selection in Myelofibrosis in the First Line and Beyond

June 9th 2024

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

Efficacy and Safety of Pirtobrutinib Continue to Reshape MCL Treatment Paradigm

May 13th 2024

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

May 6th 2024

Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.

Multidisciplinary Collaboration Plays Key Role in Pancreatic Cancer

May 2nd 2024

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL

May 2nd 2024

Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.

Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer

April 25th 2024

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.

ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology

April 24th 2024

Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.

NEXT PAGE
PREVIOUS PAGE